A holistic approach to low vision rehabilitation needed

Article

A more holistic approach to patient referral and rehabilitation provision for people with low vision is required.

A more holistic approach to patient referral and rehabilitation provision for people with low vision is required, according to a report published in the February issue of the British Journal of Ophthalmology.

P. M O'Connor and colleagues from the Centre for Eye Research Australia, University of Melbourne and Vision CRC, Sydney, Australia conducted a study to determine the independent predictors of rehabilitation needs for people with low vision using the Impact of Vision Impairment questionnaire (IVI).

A total of 477 patients attending low vision clinics completed the IVI and provided personal and clinical information such as co-morbidities and visual acuity (VA). Rasch analysis was used to generate person measures for the IVI total and three domain scores. Rehabilitation needs were based on mild, moderate or severe levels of restriction in participation as determined by the lower, moderate and higher tertiles of persons' measures. Logistic regression analyses were used to determine independent predictors of rehabilitation needs.

The majority of patients (74%) had moderate or severe vision loss and 43% had age-related macular degeneration (AMD). The results demonstrated that women, shorter duration of vision impairment, the presence of AMD, worse VA, a greater impact of co-morbidities on daily living and reliance on family or friends were univariately associated with poorer IVI scores (p<0.05). In all regression models, VA, the impact of co-morbidities on daily living and dependence on family or friends emerged as the three strongest independent predictors of rehabilitation needs.

The study concluded that, in addition to vision, clinicians should also consider issues relating to dependency when assessing rehabilitation needs.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.